Identification of TIM-3 as a Leukemic Stem Cell Surface Molecule in Primary Acute Myeloid Leukemia

Research output: Contribution to journalReview article

9 Citations (Scopus)

Abstract

Acute myeloid leukemia (AML) originates from self-renewing leukemic stem cells (LSCs), an ultimate therapeutic target in AML. Eradication of LSCs should be a critical and efficient therapeutic approach for the cure of AML. T-cell immunoglobulin mucin-3 (TIM-3) is expressed in most types of AML LSCs, but not in normal hematopoietic stem cells (HSCs); therefore, TIM-3 would be one of the promising therapeutic targets to specifically kill AML LSCs, sparing normal HSCs. In xenograft models reconstituted with human AML LSCs or human normal HSCs, an anti-human TIM-3 mouse antibody with cytotoxic activities exerts a potent anti-leukemic effect by targeting AML LSCs but does not affect normal human hematopoiesis in vivo. Here, we would like to introduce the recent studies on TIM-3 in normal and malignant hematopoiesis.

Original languageEnglish
Pages (from-to)28-32
Number of pages5
JournalOncology
Volume89
DOIs
Publication statusPublished - Jan 1 2015

Fingerprint

Mucin-3
Acute Myeloid Leukemia
Immunoglobulins
Stem Cells
T-Lymphocytes
Hematopoietic Stem Cells
Hematopoiesis
Heterografts
Therapeutics

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Identification of TIM-3 as a Leukemic Stem Cell Surface Molecule in Primary Acute Myeloid Leukemia. / Kikushige, Yoshikane; Miyamoto, Toshihiro.

In: Oncology, Vol. 89, 01.01.2015, p. 28-32.

Research output: Contribution to journalReview article

@article{8bbc971284784e43ab551c8ec95537d7,
title = "Identification of TIM-3 as a Leukemic Stem Cell Surface Molecule in Primary Acute Myeloid Leukemia",
abstract = "Acute myeloid leukemia (AML) originates from self-renewing leukemic stem cells (LSCs), an ultimate therapeutic target in AML. Eradication of LSCs should be a critical and efficient therapeutic approach for the cure of AML. T-cell immunoglobulin mucin-3 (TIM-3) is expressed in most types of AML LSCs, but not in normal hematopoietic stem cells (HSCs); therefore, TIM-3 would be one of the promising therapeutic targets to specifically kill AML LSCs, sparing normal HSCs. In xenograft models reconstituted with human AML LSCs or human normal HSCs, an anti-human TIM-3 mouse antibody with cytotoxic activities exerts a potent anti-leukemic effect by targeting AML LSCs but does not affect normal human hematopoiesis in vivo. Here, we would like to introduce the recent studies on TIM-3 in normal and malignant hematopoiesis.",
author = "Yoshikane Kikushige and Toshihiro Miyamoto",
year = "2015",
month = "1",
day = "1",
doi = "10.1159/000431062",
language = "English",
volume = "89",
pages = "28--32",
journal = "Oncology",
issn = "0030-2414",
publisher = "S. Karger AG",

}

TY - JOUR

T1 - Identification of TIM-3 as a Leukemic Stem Cell Surface Molecule in Primary Acute Myeloid Leukemia

AU - Kikushige, Yoshikane

AU - Miyamoto, Toshihiro

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Acute myeloid leukemia (AML) originates from self-renewing leukemic stem cells (LSCs), an ultimate therapeutic target in AML. Eradication of LSCs should be a critical and efficient therapeutic approach for the cure of AML. T-cell immunoglobulin mucin-3 (TIM-3) is expressed in most types of AML LSCs, but not in normal hematopoietic stem cells (HSCs); therefore, TIM-3 would be one of the promising therapeutic targets to specifically kill AML LSCs, sparing normal HSCs. In xenograft models reconstituted with human AML LSCs or human normal HSCs, an anti-human TIM-3 mouse antibody with cytotoxic activities exerts a potent anti-leukemic effect by targeting AML LSCs but does not affect normal human hematopoiesis in vivo. Here, we would like to introduce the recent studies on TIM-3 in normal and malignant hematopoiesis.

AB - Acute myeloid leukemia (AML) originates from self-renewing leukemic stem cells (LSCs), an ultimate therapeutic target in AML. Eradication of LSCs should be a critical and efficient therapeutic approach for the cure of AML. T-cell immunoglobulin mucin-3 (TIM-3) is expressed in most types of AML LSCs, but not in normal hematopoietic stem cells (HSCs); therefore, TIM-3 would be one of the promising therapeutic targets to specifically kill AML LSCs, sparing normal HSCs. In xenograft models reconstituted with human AML LSCs or human normal HSCs, an anti-human TIM-3 mouse antibody with cytotoxic activities exerts a potent anti-leukemic effect by targeting AML LSCs but does not affect normal human hematopoiesis in vivo. Here, we would like to introduce the recent studies on TIM-3 in normal and malignant hematopoiesis.

UR - http://www.scopus.com/inward/record.url?scp=84960981883&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84960981883&partnerID=8YFLogxK

U2 - 10.1159/000431062

DO - 10.1159/000431062

M3 - Review article

C2 - 26551150

AN - SCOPUS:84960981883

VL - 89

SP - 28

EP - 32

JO - Oncology

JF - Oncology

SN - 0030-2414

ER -